A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer (0683-008)

Cancer, Advanced Clinical Trial

Official title:
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer

Status Completed

Clinical Trial Summary

This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK0683 in patients with advanced cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Cancer, Advanced

Clinical Trial Details

NCT number	NCT00750178
Study type	Interventional
Source	Merck Sharp & Dohme Corp.
Contact
Status	Completed
Phase	Phase 1
Start date	November 1, 2004
Completion date	November 1, 2005

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT04604873` - The Integrated Support and Palliative in Cancer Day-care Hospital for Patients With Advanced Cancers: Impact on Quality of Life, Care Pathways and Support for Caregivers (HDJ-SPI)	N/A
Recruiting	`NCT04028479` - The Registry of Oncology Outcomes Associated With Testing and Treatment
Recruiting	`NCT05200572` - Study of a Behavioral Intervention for Older Advanced Cancer Patients and Their Caregivers	N/A
Recruiting	`NCT03896958` - The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
Recruiting	`NCT03383094` - Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer	Phase 2
Not yet recruiting	`NCT03763396` - Azoles Targeting Recurrent High Grade Gliomas	Early Phase 1
Completed	`NCT01380184` - Pharmacokinetics of Ridaforolimus (MK-8669) in Chinese Participants (MK-8669-059)	Phase 1
Withdrawn	`NCT03123744` - Histology-Independent Study of Palbociclib in Patients With Advanced Cancer	Phase 2
Recruiting	`NCT03452774` - SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry